American Journal of Cardiology
Volume 104, Issue 2 , Pages 151-157 , 15 July 2009

Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial)

  • Robert M. Califf, MD

      Affiliations

    • Duke Translational Medicine Institute, Durham, North Carolina
    • Corresponding Author InformationCorresponding author: Tel: (919) 668-8820; fax: (919) 668-7103
    • ,
  • Yuliya Lokhnygina, PhD

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
    • ,
  • Eric J. Velazquez, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
    • ,
  • John J.V. McMurray, MD

      Affiliations

    • Western Infirmary, Glasgow, Scotland, United Kingdom
    • ,
  • Jeffrey D. Leimberger, PhD

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
    • ,
  • Eldrin F. Lewis, MD, MPH

      Affiliations

    • Department of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Rafael Diaz, MD

      Affiliations

    • Estudios Cardiologicos Latinoamerica, Rosario, Argentina
    • ,
  • Jan Murin, MD

      Affiliations

    • First Medical Clinic, University Hospital, Bratislava, Slovak Republic
    • ,
  • Marc A. Pfeffer, MD

      Affiliations

    • Department of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts

Received 2 January 2009 ,Revised 3 March 2009 ,Accepted 3 March 2009.

References 

  1. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–1906
  2. Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J. 2000;140:727–750
  3. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–766
  4. Cohn JN, Tognoni G Valsartan Heart Failure Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675
  5. Lee KL, McNeer JF, Starmer CF, Harris PJ, Rosati RA. Clinical judgement and statistics (Lessons from a simulated randomized trial in coronary artery disease). Circulation. 1980;61:508–515
  6. ISIS-2 Collaboration Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected myocardial infarction. Lancet. 1988;332:349–360
  7. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266:93–98
  8. Pfisterer M, Cox JL, Granger CB, Brener SJ, Naylor CD, Califf RM, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol. 1998;32:634–640
  9. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1622–1632
  10. Reed SD, McMurray JJV, Velazquez EJ, Schulman KA, Califf RM, Kober L, et al. Geographic variation in the treatment of acute myocardial infarction in the VALIANT trial. Am Heart J. 2006;152:500–508
  11. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001;37:1950–1956
  12. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA. 1998;280:623–629
  13. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559

PII: S0002-9149(09)00724-3

doi: 10.1016/j.amjcard.2009.03.020

American Journal of Cardiology
Volume 104, Issue 2 , Pages 151-157 , 15 July 2009

Article Tools

* Image Usage & Resolution